¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high risk infant"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high dose rate intraluminal radiotherapy
    °í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • high energy compound
    °í¿¡³ÊÁöÈ­ÇÕ¹°
  • high energy phosphate compound
    °í¿¡³ÊÁöÀλ꿰ȭÇÕ¹°
  • high field magnetic resonance scanner
    °íÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • high flow method
    °íÀ¯·®¹ý
  • high forceps
    °íÀ§Áý°Ô, À§ÂÊÁý°Ô
  • high forceps delivery
    °íÀ§Áý°ÔºÐ¸¸(¼ú), °íÀ§°âÀںи¸(¼ú)
  • high frequency current
    °íÁÖÆÄÀü·ù
  • high frequency filter
    °íÁÖÆÄ¿©°ú±â, °íÁ֯İŏ£°³
  • high frequency recombination
    °íºóµµÀçÁ¶ÇÕ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ¿ëÇØ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high insertion
    °íÀ§ºÎÂø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • radiation risk
    ¹æ»ç¼±À§Çèµµ
  • recurrence risk
    Àç¹ßÀ§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • risk ratio
    À§Çèµµºñ
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
  • high power application
    °íÃâ·ÂÀû¿ë
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high frequency current
    °íÁÖÆÄÀü·ù
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high-performance liquid chromatography
    °íÀÛÀ§¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-pressure liquid chromatography
    °í¾Ð·Â¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high dizziness
    °í¼ÒÇö±âÁõ(Ë­ËÛ̴˻̡).
  • high dose rate
    °í¼±·®À²
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    °ú·®°ü¿ë
  • high echo area
    °í ¿¡ÄÚ ±¸¿ª
  • high echo area
    °í (ÍÔ) ¿¡ÄÚ ¿ª (æ´)
  • high electron density
    °íÀüÀڹеµ(ÍÔï³í­ÚËöô).
  • high energy bond
    °í¿¡³ÊÁö °áÇÕ
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ.
  • high energy phosphate bond
    °í¿¡³ÊÁöÀλ꿰°áÇÕ.
  • high energy radiation
    °í¿¡³ÊÁö¹æ»ç¼±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • infant ³ª infans
    ¿µ¾Æ( ä®), À¯¾Æ.
  • infant-mother interaction
    ¿µ¾Æ-¸ð »óÈ£ÀÛ¿ë
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ.
  • low birth wight infant
    ÀúüÁßÃâ»ý¾Æ(î¸ô÷ñìõóßæä®)
  • macerated infant
    ħ¿¬À¯¾Æ(öÙæãêêä®).
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý (ÇÐ)(ËÎËÛ ËâËôË×̰).
  • mature infant
    ¼º¼÷¾Æ, (ºÏ) ¼º¼÷¾Æ
  • mature infant
    ¼º¼÷¾Æ(à÷âÙä®).
  • mother-infant bond
  • mother-infant complex
  • mother-infant dyad
  • newborn infant
    ½Å»ý¾Æ.
  • nfant,sudden infant death syndrome
    ¿µ¾Æ±Þ»çÁõÈıº(¿µä®ÐáÞÝñøý¦ÏØ)
  • nursing infant
    ¾çÀ°¿µ¾Æ, ¼öÀ¯¿µ¾Æ, À°¾Æ(ëÀä®).
  • premature infant
    ¹Ì¼÷¾Æ(Ú±âÙä®), Á¶»ê¾Æ(ðÄß§ä®).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HFO high-frequency oscillator; high-frequency oscillatory [ventilation]
HFT high-frequency transduction; high-frequency transfer
HIHA high impulsiveness, high anxiety
HPF heparin-precipitable fraction; hepatic plasma flow; high-pass filter; high-power field [microscope];...
HV hallux valgus; Hantaan virus; heart volume; hepatic vein; herpesvirus; high voltage; high volume; ho...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BRFSS Behavioral Risk Factor Surveillance System
CVRF Cardiovascular risk factor
CRIB Clinical Risk Index for Babies
CARDIA Coronary Artery Risk Development In Young Adults
CORIS Coronary Risk Factor Study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high vacuum
    °íÁø°ø
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • high voltage radiography
    °í¾Ð ¹æ»ç¼± ÃÔ¿µ¼ú, °í¾Ð ÃÔ¿µ¼ú, °íÀü¾Ð ÃÔ¿µ¼ú
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • high-density lipoprotein
    °í¹Ðµµ Áö¹æ ´Ü¹é
  • high-energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÌ °áÇÕÀº ¾Æµ¥³ë½Å »ïÀλê, Æ÷½ºÆ÷Å©·¹¾ÆÆ¾, ´ç´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high-energy sulfer bond
    °í¿¡³ÊÁö À¯È² °áÇÕ
    ÀÌ °áÇÕ¿¡¼­ °¡Àå Áß¿äÇÑ °ÍÀº ¾Æ¼¼Æ¿ CoA¿¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î¼­ Áö¹æ»ê »ýÇÕ¼ºÀÇ ÁÖ¿ä ¿¡³ÊÁö¿øÀÌ µÈ´Ù.
  • high-frequency oscillation
    °íÁÖÆÄ Áøµ¿
  • high-power interaction
    °íÃâ·Â »óÈ£ ÀÛ¿ë
  • high-speed grinding
    °í¼Ó »èÁ¦
    ºü¸¥ ¼Óµµ·Î °¥¾Æ³»´Â °Í.
  • high-threshold class
    °í¿ªÄ¡±º
    ¿ªÄ¡ÀÇ Å©±â°¡ ³ôÀº Áý´Ü.
  • high-threshold mechanoreceptor
    °í¿ªÄ¡ ±â°è ¼ö¿ëü, °í¿ªÄ¡ ±â°è ¼ö¿ë±â
  • high-threshold neuron
    °í¿ªÄ¡ ´º¿ì·±
    ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â µ¥ Å« ÀÚ±ØÀÌ ÇÊ¿äÇÑ ´º¿ì·±.
  • high-voltage stimulation
    °íÀü¾Ð ÀÚ±Ø
    ³ôÀº Àü¾ÐÀÇ Àü±â ÀÚ±Ø.
  • paramagnetic high susceptibility
    »óÀÚ¼º °íÀÚÈ­À²
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
infant mortality rate The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
infant, newborn An infant during the first month after birth.
(12 Dec 1998)
infant, newborn, diseases Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both hereditary diseases and metabolism, inborn errors are available as general concepts.
(12 Dec 1998)
infant nutrition Nutrition of children from birth to 2 years of age.
(12 Dec 1998)
infant nutrition disorders Malnutrition, occurring in infants ages 1 month to 24 months, which is due to insufficient intake of food, dietary nutrients, or a pathophysiologic condition which prevents the absorption and utilization of food. Growth and development are markedly affected.
(12 Dec 1998)
infant, postmature An infant born at or after 42 weeks of gestation.
(12 Dec 1998)
infant, premature An infant born before 38 weeks of gestation.
(12 Dec 1998)
infant, small for gestational age An infant having a birth weight lower than expected for its gestational age.
(12 Dec 1998)
infant, very low birth weight An infant having a birth weight of 1500 grams (3.3 lb.) or less.
(12 Dec 1998)
infant welfare Organised efforts by communities or organizations to improve the health and well-being of the infant.
(12 Dec 1998)
term infant An infant with gestational age between 37 completed weeks (259 completed days) and 42 completed weeks (294 completed days).
(05 Mar 2000)
liveborn infant The product of a livebirth; an infant who shows evidence of life after birth; life is considered to be present after birth if any one of the following is observed: 1) if the infant breathes; 2) if the infant shows beating of the heart; 3) if pulsation of the umbilical cord occurs; or 4) if there is definite movement of voluntary muscles.
(05 Mar 2000)
blood pressure, high High blood pressure (hypertension) is a repeatedly elevated blood pressure exceeding 140 over 90 mmHg. High blood pressure is also called the silent killer. Chronically high blood pressure can cause blood vessel changes in the back of the eye (retina), thickening of the heart muscle, kidney failure, and brain damage. No specific cause for high blood pressure is found in 95% of patients. High blood pressure is treated with salt restriction, regular aerobic exercise, and medications.
(12 Dec 1998)
blood sugar, high Elevated levels of blood glucose (hyperglycaemia) can be found in a number of conditions. The hyperglycaemia leads to spillage of glucose into the urine, hence the term sweet urine. (Diabetes mellitus means sweet urine. )
(12 Dec 1998)
cardiac output, high A state of elevated cardiac output. Conditions that lower peripheral vascular resistance, such as anaemia, arteriovenous fistulas, thyrotoxicosis, and pregnancy, are among the most important factors augmenting the venous return and therefore elevating cardiac output. Increased cardiac output also occurs in muscular exercise, fever, and severe anoxia.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high beam
    ÇÏÀ̺ö(¿ø°Å¸®¿ë »óÇâ Çìµå¶óÀÌÆ®)
  • high blood pressure
    °íÇ÷¾Ð
  • high blower
    Äà±èÀ» ¼¼°Ô ³»½¬´Â ¸»
  • high boot
    ÀåÈ­
  • high brass
    =top brass
  • high camp
    ¿¹¼úÀûÀ¸·Î ÁøºÎÇÑ °ÍÀ» ÀǵµÀûÀ¸·Î ÀÌ¿ëÇϱâ
  • high chair
    (¾î¸°ÀÌÀÇ)½Ä»ç¿ë ³ôÀº ÀÇÀÚ
  • high color
    ÁÁÀº Ç÷»ö
  • high comedy
    (¿¬±âÀÇ ÀÍ»ì µûÀ§¿¡ ÁßÁ¡À» µÎÁö ¾Ê´Â)°í±ÞÈñ±Ø
  • high command
    ÃÖ°í »ç·ÉºÎ
  • high commissioner
    (½Ä¹ÎÁöÀÇ)°íµî ÆÇ¹«°ü !
  • high crime
    Áß´ëÇÑ ¹üÁË(´ëÅë·É ±âŸ ÇàÁ¤°üÀÇ ÅºÇÙ ÀÌÀ¯°¡ µÇ´Â ÆÄ·ÅÄ¡ ¹üÁË)
  • high day
    ÃàÁ¦ÀÏ
  • high day
    ÃàÁ¦ÀÏ;°æÃàÀÏ
  • high explosive
    °í¼º´É Æø¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á